- Home
- PAXS vs VTYX Comparison
PAXS vs VTYX Comparison
Compare PAXS & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAXS | VTYX |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.2M | 713.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAXS | VTYX |
|---|---|---|
| Price | $15.69 | $13.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.60 |
| AVG Volume (30 Days) | 195.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 11.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.57 | $0.78 |
| 52 Week High | $15.93 | $25.00 |
Technical Indicators
Market Signals| Indicator | PAXS | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 55.87 | 75.47 |
| Support Level | $15.23 | $7.08 |
| Resistance Level | $15.54 | $9.30 |
| Average True Range (ATR) | 0.15 | 0.74 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 87.76 | 80.63 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.